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Carlos Hermenegildo,2,3 Concepción Peiró,4 Laura Piqueras,2,* and Maria-Jesus Sanz1,2,*
Abstract
Aim: Mononuclear cell (MC) infiltration into the arterial subendothelium is a key event in atherogenesis.
Rosuvastatin (Rosu) and bexarotene (Bex) exert anti-inflammatory activity, but serious dose-related adverse
effects have emerged. The need for safer and effective strategies to prevent and treat atherosclerosis led us to
test the effect of combined use of both drugs on angiotensin II (Ang-II)-induced arterial MC recruitment.
Results: Vehicle, Rosu (10–30 nM), Bex (0.3–1 lM), or a combination of both were administered to human
umbilical arterial endothelial cells (HUAECs) 20 h before stimulation with 1 lM Ang-II (4 h). Surprisingly, a
combination of Rosu (10 nM)+Bex (0.3 lM), which did not influence Ang-II-induced MC recruitment when
either stimulus was studied alone, significantly reduced this response. This effect was accompanied by di-
minished Ang-II-induced ICAM-1, VCAM-1, and CX3CL1 endothelial expression and CXCL1, CXCL8,
CCL2, and CCL5 production. Preincubation of HUAECs with Rosu+Bex inhibited Nox5 expression and Nox5-
induced RhoA activation stimulated by Ang-II through increased RXRa, PPARa, and PPARc expression in
addition to RXRa/PPARa and RXRa/PPARc interactions. In vivo, combined but not single administration of
Rosu (1.25 mg/kg/day) and Bex (10 mg/kg/day) significantly diminished Ang-II-induced arteriolar leukocyte
adhesion in the cremasteric microcirculation of C57BL/6 mice and atherosclerotic lesion formation in apoE - / -
mice subjected to an atherogenic diet. Innovation and Conclusion: Combined administration of Bex+Rosu at
suboptimal doses may constitute a new alternative and effective therapy in the control of the vascular in-
flammation associated to cardiometabolic disorders, since they synergize in their anti-inflammatory actions and
may counteract their associated adverse effects. Antioxid. Redox Signal. 22, 901–920.
Introduction
Increased levels of circulating mediators, includingangiotensin II (Ang-II) and cytokines, have been detected
in cardiovascular and cardiometabolic diseases such as hy-
pertension, obesity, and diabetes, and can exert deleterious
effects on endothelial function (18, 34). These agents initiate an
inflammatory signaling cascade associated with reactive oxy-
gen species (ROS) generation, increased cell-surface expres-
sion of cell adhesion molecules (CAMs), and enhanced
leukocyte adhesiveness to endothelial cells (18, 31). These
responses are associated with endothelial dysfunction, and a
pro-thrombotic and pro-inflammatory state of the endothelium
(28) contributes to the early stages of atherogenesis (14, 28, 31).
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Ang-II is implicated in atherogenesis (9), and we demon-
strated that 4 h of exposure to Ang-II in vivo caused arteriolar
leukocyte adhesion in the mesenteric microcirculation of the rat
(2). Notably, mononuclear leukocyte recruitment by Ang-II
was found to be mediated largely by tumor necrosis factor-a
(TNFa) and the subsequent increased endothelial expression of
fractalkine (CX3CL1)(37, 54). Consequently, pharmacological
modulation of inflammatory cell infiltration of the subendo-
thelial space may impede the atherogenic process associated
with different cardiovascular risk factors related to the rennin-
angiotensin system.
Statins are a group of 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors that were primarily used because
of their lipid-lowering properties due to their capacity to block
cholesterol biosynthesis (1). Thereafter, their ability to reduce
cardiovascular mortality and stroke was found to go beyond
their lipid-lowering attributes. Indeed, when rosuvastatin
(Rosu) was administered to healthy subjects without hyper-
lipidemia but with elevated high-sensitivity C-reactive protein
levels, the incidence of major cardiovascular events was re-
duced (52). These so-called pleiotropic effects of statins in-
clude modulation of inflammatory reactions and anti-oxidant
properties, which may additionally play important roles in
statin-mediated cardiovascular protection (38). Accordingly,
there is evidence indicating that statins favorably influence
endothelial cell function (38) and impair leukocyte trafficking
at sites of inflammation (59). Furthermore, a growing body of
experimental data suggests a potential interplay between sta-
tins and peroxisome proliferator-activated receptors (PPARs)
(3, 6), and activation of PPARs can downregulate the ex-
pression of CAMs, proinflammatory genes, and leukocyte-
endothelial cell interactions (40). Though statins in general are
well tolerated, myopathy and acute renal events have been a
significant concern with the use of high-potency statin drugs,
in particular simvastatin and Rosu (8, 15, 23). Since these
adverse effects are frequently dose related (8, 15, 23), there
remains an overt need to identify agents that, when combined
with statins, can provide the greatest benefit on cardiovascular
disease with the least added risk.
Bexarotene (Bex) is a retinoid X receptor (RXR)-selective
agonist currently used in the treatment of cutaneous T-cell
lymphoma. We have previously shown that Bex can inhibit
mononuclear leukocyte attachment to stimulated arterial en-
dothelial cells through downregulation of redox-sensitive
pathways and via RXR/PPARc interaction (12, 55). Indeed, it
is well established that PPARs form permissive RXR hetero-
dimers that synergistically respond to agonists of RXR and the
partner receptor (49). Unfortunately, Bex treatment is associ-
ated with unavoidable and dose-limiting side effects, in par-
ticular hypertriglyceridemia, hypercholesterolemia, and, to a
lesser extent, hypothyroidism (7, 61). However, Rosu admin-
istration can reduce triglyceride levels (13) and the U.K.
consensus statement on safe clinical prescribing of Bex rec-
ommend the use of this statin to prevent the dyslipidemic
effects associated with administration of the RXR agonist (57).
In an attempt to identify more effective strategies to treat
and prevent atherosclerosis, coronary heart disease, and co-
morbid metabolic disorders characterized by endothelial dys-
function, we have evaluated the effect of combined treatment
with Rosu and Bex. In this study, we provide both in vitro and
in vivo evidence that the combination of Rosu + Bex at sub-
optimal concentration/doses provokes a clear impairment in
Ang-II-induced mononuclear cell (MC) adhesion to the arte-
rial endothelium. The underlying mechanisms involved in this
beneficial synergism were also explored. We found that Nox5
downregulation and subsequent RhoA inactivation were in-
volved in these responses. Furthermore, increased RXR/
PPARa and RXR/PPARc interactions were, in part, responsi-
ble for the observed anti-inflammatory activity.
Results
A combination of Rosu and Bex at suboptimal
concentrations reduces Ang-II-induced human
umbilical artery endothelial cell MC adhesion
Initially, we evaluated the effect of Ang-II challenge on
mononuclear leukocyte-endothelial cell interactions in vitro
using the dynamic flow chamber assay. Thus, freshly isolated
human MCs were perfused across human umbilical artery
endothelial cell (HUAEC) monolayers stimulated or not with
Ang-II (1 lM) for 4 h. Ang-II caused a significant increase in
mononuclear leukocyte adhesion to arterial endothelial cells
(Fig. 1). To assess the effect of Rosu on Ang-II-induced MC
recruitment, HUAECs were pretreated with the statin at two
different concentrations (10 and 30 nM), 20 h before Ang-II
stimulation. While 10 nM Rosu had no impact on Ang-II-
induced MC recruitment, preincubation with 30 nM Rosu
significantly reduced Ang-II-induced mononuclear leukocyte
adhesion (Fig. 1A). A similar approach was followed to test
the effect of Bex preincubation on Ang-II-induced responses,
based on previous observations (55). As anticipated, 1 lM but
not 0.3 lM Bex significantly inhibited MC adhesion to Ang-
II-stimulated HUAECs (Fig. 1B). To evaluate the potential
synergism of both drugs, different combinations of Rosu and
Bex were assessed. All the combinations tested significantly
impaired Ang-II-induced MC attachment to the arterial en-
dothelium (Fig. 1C). Unexpectedly, the combination of Rosu
at 10 nM and Bex at 0.3 lM, which displayed no significant
effect when either treatment was tested alone, reduced ad-
hesion by 51% (Fig. 1C). Consequently, in all subsequent
in vitro experiments, this combination of Rosu and Bex
(designated Rosu + Bex) was employed to explore the un-
derlying mechanisms involved in this response.
In addition, since there is evidence to support that Ang-II
can decrease AT1 receptor expression, although in vascular
smooth muscle cells (44), we evaluated this possibility. As
illustrated in Supplementary Figure S1 (Supplementary Data
Innovation
These findings highlight a promising new and safer
therapeutic approach in the management of vascular in-
flammation that precedes or accompanies most cardio-
vascular disorders using two clinically available drugs.
The synergistic anti-inflammatory effect was the conse-
quence of increased RXRa, PPARa, and PPARc expres-
sion as well as of RXRa/PPARa and RXRa/PPARc
interactions, leading to the inhibition of Nox5-mediated
signaling pathways. Moreover, this new therapeutic re-
gime results in minimal drug-associated side effects since
low doses of both drugs are used, and rosuvastatin ad-
ministration may beneficially counteract the dyslipidemic
state linked to the chronic treatment with Bexarotene.
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are available online at www.liebertpub.com/ars), we found
that neither Ang-II stimulation for 4 h nor the pretreatment of
the endothelial cells with the drugs, in combination or alone,
affected AT1 receptor expression.
Decreased expression of ICAM-1 and VCAM-1
is involved in the reduced Ang-II-induced HUAEC-MC
adhesion caused by suboptimal concentrations
of Rosu + Bex
To investigate whether the inhibitory effects exerted by
Rosu + Bex on Ang-II-induced mononuclear leukocyte ad-
hesion were mediated through modulation of endothelial
CAM expression, intercellular adhesion molecule-1 (ICAM-
1) and vascular cell adhesion molecule-1 (VCAM-1) protein
expression were determined by flow cytometry and immu-
nocytochemistry. Stimulation with Ang-II resulted in a sig-
nificant upregulation of ICAM-1 and VCAM-1 expression
when compared with unstimulated control HUAECs, as
measured by both flow cytometry and immunofluorscence
(Fig. 2A, B). Pretreatment of cells with Rosu or Bex did not
modify the increased endothelial CAM expression induced
by the peptide (Fig. 2A, B). In contrast, preincubation of
HUAEC with Rosu + Bex resulted in a significant decrease in
Ang-II-induced ICAM-1 and VCAM-1 expression, by 42%
and 66%, respectively (Fig. 2A, B).
Inhibition of Ang-II-induced HUAEC chemokine
synthesis by combination of Rosu + Bex at suboptimal
concentrations
Since Ang-II stimulation of endothelial cells can induce
the production and release of different CXC and CC che-
mokines, in addition to the expression of the membrane-
bound chemokine fractalkine (36, 42, 54), we next evaluated
the effect of Rosu + Bex on Ang-II-induced chemokine syn-
thesis in human arterial endothelial cells. Significant in-
creases in the levels of growth-regulated oncogene-a (GROa
or CXCL1), interleukin-8 (IL-8 or CXCL8), monocyte che-
motactic protein-1 (MCP-1 or CCL2), and regulated on ac-
tivation, normal T cell expressed and secreted (RANTES or
CCL5) were detected in the supernatant of HUAEC subjected
to Ang-II stimulation for 4 h, as measured by enzyme-linked
immunoassay (ELISA) (Fig. 3A–D). This increase was not
inhibited when HUAECs were preincubated with either of the
drugs alone, but was markedly diminished by pretreatment of
cells with the combination of Rosu + Bex (Fig. 3A–D). Si-
milarly, when HUAECs were stimulated with 1 lM Ang-II
for 24 h, a significant increase in the expression of fractalkine
was observed, by both flow cytometry and immunofluores-
cence (Fig. 3E, F). Again, preincubation of cells with
Rosu + Bex caused a significant downregulation of the cell-
membrane chemokine expression (Fig. 3E, F).
Combination of Rosu + Bex at suboptimal
concentrations inhibits Ang-II-induced HUAEC RhoA
activation and subsequent MC recruitment
It is well recognized that small GTP-binding proteins (G-
proteins), such as Ras, Rho, and Rac, are activated by Ang-II
through interaction with its AT1 receptor (22). To charac-
terize the signaling mechanisms by which Rosu + Bex mod-
ulate arterial MC adhesion stimulated by Ang-II, we first
established their effect on Ang-II-induced RhoA activation.
As illustrated in Figure 4A, Ang-II stimulation of HUAEC for
FIG. 1. Combination of Rosuvastatin
(Rosu) and Bexarotene (Bex) at subopti-
mal concentrations reduces angiotensin II
(Ang-II)-induced human umbilical artery
endothelial cell (HUAEC) mononuclear
cell adhesion under physiological flow.
HUAECs were stimulated with Ang-II
(1 lM) for 4 h. In some experiments, cells
were pretreated with Rosu (10–30 nM) (A),
Bex (0.3–1 lM) (B), or combinations of both
(C), 20 h before Ang-II stimulation. Freshly
isolated human mononuclear cells (106 cells/
ml) were perfused across the endothelial
monolayers for 5 min at 0.5 dyn/cm2, and
leukocyte adhesion was quantified. Results
are the mean – SEM of n = 5 independent
experiments; **p < 0.01 relative to the ve-
hicle group, ++ p < 0.01 relative to the Ang-
II-stimulated cells.
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1 h caused a significant increase in RhoA activation. Whereas
pretreatment of cells with Rosu or Bex 20 h before Ang-II
stimulation failed to modify RhoA activation, preincubation
with the combination Rosu + Bex caused a significant inhi-
bition of this response (Fig. 4A). To evaluate the impact of
RhoA activation on Ang-II-induced MC recruitment, we si-
lenced RhoA expression in endothelial cells with small in-
terfering RNA (siRNA). Forty–eight hours after transfection
with RhoA–specific siRNA, HUAEC exhibited a > 69%
reduction in RhoA protein compared with control siRNA-
treated cells (Fig. 4B). Ang-II stimulation (1 lM, 4 h) pro-
duced a significant increase in MC arrest in control siRNA
cells, which was abrogated in RhoA-silenced HUAECs (Fig.
4C). Furthermore, inhibition of the RhoA downstream target,
Rho-associated protein kinase (ROCK), resulted in a signif-
icant impairment in Ang-II-induced arterial mononuclear
leukocyte adhesion (Supplementary Fig. S2).
Combination of Rosu + Bex at suboptimal
concentrations inhibits Ang-II-induced Nox5
expression in HUAECs
The production of ROS and subsequent activation of redox-
sensitive signaling pathways mediates many of the inflam-
matory responses induced by Ang II (29, 30). Accordingly,
endothelial Ang-II stimulation activated NADPH oxidase in
HUAECs (Fig. 5A). Notably, this activation was diminished
by cell pretreatment with Rosu + Bex, but not when either drug
was used separately (Fig. 5A). Ang-II caused increased en-
dothelial expression of Nox2, Nox4, and Nox5 (54) and Figure
5B–D. Interestingly, while the expression of these Nox iso-
forms induced by Ang-II were unaffected by Rosu or Bex
pretreatment of the cells, Nox2 and Nox5 but not Nox4 ex-
pression was markedly reduced by preincubation with
Rosu + Bex (Fig. 5B–D). Since MC arrest was found to be
largely mediated via endothelial Nox5 expression (54) and
ROS generation can activate RhoA (43), we next questioned
whether the absence of endothelial Nox5 or antioxidant pre-
treatment resulted in a failure to activate this GTP-binding
protein. To do this, we used both siRNA targeting Nox5 and the
antioxidant apocynin. Nox5 protein expression was signifi-
cantly reduced (62%) after 48 h of incubation with a specific
siRNA (Supplementary Figs. S3 and S4). Further, knockdown
of Nox5 or apocynin pretreatment resulted in the blockade of
Ang-II-induced RhoA activation (Fig. 5E, F). Conversely, in
RhoA-silenced HUAECs, or in HUAECs pretreated with an
RhoA inhibitor (cell-permeable C3 transferase), the increased
expression of Nox5 protein triggered by Ang-II remained un-
changed (Fig. 5G, H). Moreover, while Ang-II-induced endo-
thelial ROS generation was neutralized by preincubation with
apocynin, it was unaffected by pretreatment of the cells with the
RhoA inhibitor (Supplementary Fig. S5).
Suboptimal concentrations of Rosu + Bex provokes
increased expression of endothelial RXRa, PPARa,
and PPARg
Given that statins and Bex can activate PPARs and RXRa
nuclear receptors, respectively (3, 6, 55), we investigated
whether the combination of Rosu + Bex exerted its inhibitory
activity through changes in the endothelial expression of
RXRa, PPARa, PPARb/d, or PPARc. Immunoblot analysis
showed that Ang-II-stimulated HUAECs, preincubated or not
with Ros or Bex alone, expressed comparable levels of RXRa
and PPAR nuclear receptors to vehicle controls (Fig. 6A–D).
Importantly, when cells were treated with Rosu + Bex for
FIG. 2. Effect of Rosu1Bex
on endothelial cell adhesion
molecule expression. Cells
were treated with Rosu
(10 nM), Bex (0.3 lM), or a
combination of Rosu (10 nM)
plus Bex (0.3 lM) for 20 h and
then stimulated with Ang-II
(1 lM, 4 h). ICAM-1 (A) and
VCAM-1 (B) protein expres-
sion was determined by flow
cytometry and immunofluo-
rescence. Right panels show
representative images of endo-
thelial cells. Nuclei were coun-
terstained with DAPI (blue),
and green fluorescence shows
ICAM-1 (top) or VCAM-1
(bottom). Results are expressed
as mean fluorescence intensity
(MFI) and presented as
mean – SEM of n = 5–9 inde-
pendent experiments; **p <
0.01 relative to the vehicle
group, + p < 0.05 relative to the
Ang-II-stimulated cells.
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20 h followed by stimulation with Ang-II for 4 h, RXRa,
PPARa, and PPARc were significantly upregulated while
PPARb/d expression was unchanged (Fig. 6A–D). To under-
stand how increased expression of RXRa, PPARa, or PPARc
might contribute to the reduction of Ang-II-induced leukocyte-
endothelial cell interactions elicited by pre-exposure of
HUAEC to Rosu + Bex, we evaluated leukocyte adhesion to
HUAECs individually silenced for expression of RXRa,
PPARa, and PPARc. Knockdown of RXRa, PPARa, and
PPARc resulted in a 57–66% decrease in receptor expression
relative to control-siRNA cells (Supplementary Fig. S6). No-
tably, silencing of RXRa, PPARa, or PPARc abolished the
suppressive effects of Rosu + Bex on leukocyte adhesion to
HUAEC stimulated with Ang-II (Fig. 6E–G). Furthermore,
when HUAEC were immunoprecipitated with an anti-PPARa
or an anti-PPARc antibody, followed by immunoblotting with
an anti-RXRa antibody, enhanced dimerization of RXRa with
PPARa or PPARc was detected with Rosu + Bex, relative to
Ang-II-only stimulated cells (Fig. 6H), although the interac-
tion seemed to be more pronounced with PPARc.
Reduction of RXRa, PPARa, or PPARg expression
blunted the inhibition of Ang-II-induced HUAEC RhoA
activation and Nox5 expression by Rosu + Bex
at suboptimal concentrations
To gain further insight into the inhibitory mechanisms
involved in the Ang-II-induced MC arrest by Rosu + Bex,
FIG. 3. Suboptimal concentrations of Rosu1Bex decreases Ang-II-induced chemokine production in HUAEC. Cells
were treated with Rosu (10 nM), Bex (0.3 lM), or a combination of Rosu (10 nM) plus Bex (0.3 lM) for 20 h and then
stimulated with Ang-II (1 lM) for 4 h. GROa (A), IL-8 (B), MCP-1(C), and RANTES (D) release was determined by enzyme-
linked immunoassay (ELISA) in the cell-free supernatant. Results are expressed as pM concentration and presented as mean –
SEM of n = 7–9 independent experiments; **p < 0.01 relative to the vehicle group, + p < 0.05 or + + p < 0.01 relative to the Ang-II
stimulated cells. In a second set of experiments, HUAECs were treated with Rosu (10 nM), Bex (0.3 lM), or a combination of Rosu
(10 nM) plus Bex (0.3 lM) for 20 h and then stimulated with Ang-II (1 lM) for 24 h. CX3CL1 expression in HUAEC was
determined by flow cytometry (E) and visualized by immunofluorescence (green). Nuclei were counterstained with DAPI; images
are representatives of n = 5–7 independent experiments per group (F). Results are the mean – SEM of n = 5–7 independent
experiments; *p < 0.05 or **p < 0.01 relative to the vehicle group, + p < 0.05 relative to the Ang-II-stimulated cells.
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FIG. 4. Inhibitory effects of Rosu1Bex
at suboptimal concentrations on Ang-II-
induced HUAEC RhoA activation.
HUAEC were stimulated with Ang-II (1 lM)
for 1 h. In some experiments, cells were
treated with Rosu (10 nM), Bex (0.3 lM), or
a combination of Rosu (10 nM) plus Bex
(0.3 lM) for 20 h before Ang-II stimulation.
Quantification of RhoA-GTP activity was
determined using a colorimetric G-Lisa kit
activation RhoA assay (A). Results are the
mean – SEM of n = 6–9 independent experi-
ments and presented as percentage of con-
trol; **p < 0.01 relative to the vehicle group,
+ p < 0.05 relative to the Ang-II-stimulated
cells. A second group of cells was trans-
fected using an RhoA-specific siRNA or
control-siRNA, and at 48 h post-transfection
protein, expression was determined by im-
munoblot (B). Control or RhoA-specific
siRNA-transfected cells were stimulated
with Ang-II (1 lM) for 4 h. Then, freshly
isolated human mononuclear cells were
perfused over the endothelial monolayers for
5 min at 0.5 dyn/cm2 and leukocyte adhesion
was quantified (C). Results are the mean –
SEM of n = 5–6 independent experiments;
**p < 0.01 relative to the vehicle group,
+ + p < 0.01 relative to values in Ang-II
group in control siRNA-transfected cells.
FIG. 5. Suboptimal concentrations of Rosu1Bex decrease Ang-II-induced endothelial Nox5 expression. Endothelial
cells were incubated with Rosu (10 nM), Bex (0.3 lM), or a combination of Rosu (10 nM) plus Bex (0.3 lM) for 20 h and then
stimulated with Ang-II (1 lM, 1 h) and the generation of superoxide anions by NADPH oxidase was determined by lucigenin-
derived chemiluminiscence (A). Results (mean – SEM of four to seven independent experiments performed in duplicate) are
presented as percentage of control; **p < 0.01 relative to the vehicle group, + p < 0.05 relative to the Ang-II-stimulated cells.
HUAEC were treated with Rosu (10 nM), Bex (0.3 lM), or a combination of Rosu (10 nM) plus Bex (0.3 lM) for 20 h and then
stimulated with Ang-II (1 lM, 24 h). Nox2 (B), Nox4 (C), and Nox5 (D) expression was determined by immunoblotting.
Results (mean – SEM of five to seven independent experiments) are expressed as fold increase of Nox:b-actin. Representative
blots are shown; *p < 0.05 or **p < 0.01 relative to the vehicle group, + p < 0.05 or + + p < 0.01 relative to the Ang-II stimulated
cells. In additional experiments, control or siRNA Nox5-transfected HUAEC were stimulated with Ang-II (1 lM for 1 h) and
quantification of RhoA-GTP activity was determined as earlier (E). Results are the mean – SEM of n = 7–8 independent
experiments and are presented as percentage of control siRNA-transfected cells, **p < 0.01 relative to the respective vehicle
group, + p < 0.05 relative to the respective Ang-II-stimulated cells. In other plates, HUAEC were pretreated with the NADPH
inhibitor apocynin (30 lM) 1 h before Ang-II stimulation and quantification of RhoA activity was determined (F). Results are
the mean – SEM of n = 5 independent experiments and presented as percentage of control; **p < 0.01 relative to the vehicle-
treated group, + p < 0.05 relative to the Ang-II-stimulated cells. In a different experimental setting, cells were transfected with
control or RhoA-specific siRNA. At 48 h post transfection, HUAEC were stimulated with Ang-II (1 lM) for 4 h and Nox5
expression was quantified by immunoblot (G). Results (mean – SEM of at least five independent experiments) are expressed as
fold increase of Nox5:b-actin of control siRNA-transfected cells. A representative blot is shown above; **p < 0.01 relative to
the vehicle-treated group. Untransfected cells were pretreated with an RhoA inhibitor (C3 transferase, 2 lg/ml for 4 h) before
Ang-II stimulation, and Nox5 expression was determined by immunoblot. (H) Results (mean – SEM of at least five inde-
pendent experiments) are expressed as fold increase of Nox5:b-actin. A representative blot is shown above; **p < 0.01 relative
to the vehicle-treated group.
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HUAEC were transfected with siRNAs against RXRa,
PPARa, or PPARc. Interestingly, the inhibitory effect of
Rosu + Bex on RhoA activation or Nox5 downregulation in
cells stimulated with Ang-II was abolished in cells silenced
for these nuclear receptors (Fig. 7).
Combination of Rosu + Bex at suboptimal
concentrations restored the inhibition in nitric oxide
bioavailability induced by Ang-II in HUAECs
It is well known that Ang-II impairs endothelial function by
decreasing nitric oxide (NO) bioavailability (32, 43). These
effects can be mediated through superoxide anion generation
and a reaction with NO, resulting in its quenching to form
peroxynitrite, and endothelial NO synthase (eNOS) inhibition
and uncoupling (32, 43). Therefore, we evaluated the effect of
Rosu + Bex on the Ang-II-induced decrease in NO bioavail-
ability in HUAEC. Ang-II stimulation of the cells reduced NO
levels in HUAECs (Fig. 8A). Notably, this reduction was re-
versed by cell pretreatment with Rosu + Bex, but not when
either drug was used separately (Fig. 8A). Pretreatment of the
cells with the antioxidant apocynin or an RhoA inhibitor (cell
permeable C3 transferase) reversed the reduction in NO
availability induced by Ang-II (Fig. 8B). Similarly, silencing
of Nox5 prevented the decrease in NO bioavailability pro-
voked by Ang-II (Fig. 8C). More importantly, in the absence of
RXRa, PPARa, or PPARc, Rosu + Bex was unable to fully
restore endothelial NO levels (Fig. 8D–G).
Suboptimal doses of Rosu + Bex impairs
Ang-II-induced leukocyte-arteriolar adhesion in vivo
To connect our in vitro observations with what happens
in vivo, we utilized a chronic model of Ang-II infusion.
Animals were implanted with osmotic mini-pumps con-
stantly releasing either Ang-II (500 ng/kg/min) (56) or ve-
hicle, for 14 days. Consistent with the in vitro analysis,
animals chronically infused with Ang-II showed a significant
enhancement in arteriolar leukocyte adhesion compared with
vehicle-infused mice (Fig. 9A). Co-infusion of Rosu at
1.25 mg/kg/day, or oral administration of Bex at 10 mg/kg/
day, did not change arteriolar leukocyte adhesion caused by
Ang-II systemic infusion (Fig. 9A). However, when the an-
imals were co-infused with Ang-II plus the statin, and Bex
was co-administered daily, leukocyte adhesion was signifi-
cantly reduced by 65% (Fig. 9A). Moreover, Ang-II-induced
expression of CD11b in circulating monocytes was also re-
duced by Rosu + Bex administration, whereas neutrophil
CD11b expression was not affected by any treatment (Fig. 9B,
C). In addition, immunohistochemistry analysis of cremasteric
arterioles showed that the Ang-II-induced increase in ICAM-1,
VCAM-1, and fractalkine expression was blunted by co-
treatment with Rosu + Bex in mice (Fig. 9D). As expected, a
significant reduction in circulating levels of chemokines, in-
cluding CXCL1 and MCP-1, and a tendency for reduction in
RANTES, were also observed in animals treated with Rosu +
Bex and chronically subjected to Ang-II (Fig. 9E–G). In this
FIG. 6. Suboptimal concentrations of Rosu1Bex increase RXRa, PPARa, and PPARc but not PPARb/d expression
in HUAEC stimulated with Ang-II. RXRa, PPARa, or PPARc knockdown abolished the inhibitory effect of Rosu + Bex
on Ang-II-induced mononuclear leukocyte-endothelial cell interactions. HUAEC were incubated with Ang-II (1 lM) for 4 h.
In some experiments, cells were pretreated with Rosu (10 nM), Bex (0.3 lM), or a combination of Rosu (10 nM) plus Bex
(0.3 lM) for 20 h before Ang-II stimulation. RXRa (A), PPARa (B), PPARc (C), and PPARb/d (D) expression was
determined by immunoblot. Results (mean – SEM of n = 5–7 independent experiments) are expressed as fold increase
relative to b-actin. Representative gels are shown. + + p < 0.01 relative to the Ang-II-treated group. Cells were transfected
with control siRNA, RXRa-specific siRNA (E), PPARa-specific siRNA (F), or PPARc-specific siRNA (G) and stimulated
with Ang-II (1 lM; 4 h) at 48 h post-transfection. In some experiments, cells were pretreated with Rosu (10 nM) plus Bex
(0.3 lM) 20 h before Ang-II challenge. Freshly isolated human mononuclear cells (106 cells/ml) were perfused over the
endothelial monolayers for 5 min at 0.5 dyn/cm2, and leukocyte adhesion was quantified. Results are the mean – SEM
of n = 4–5 independent experiments. *p < 0.05 or **p < 0.01 relative to the respective vehicle group, + p < 0.05 or
+ + p < 0.01 relative to the respective Ang-II-stimulated cells. RXRa/PPARa and RXRa/PPARc interactions (H) were
assessed by immunoprecipitation of PPARa or PPARc and subsequent immunoblotting for RXRa. Blots are representative
of four independent experiments.
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experimental setting, glucose levels and lipid profile were
unaffected by the different treatments (Supplementary Table
S1). With regard to blood pressure, Ang-II infusion at this dose
caused a small but significant increase in this parameter at day
14, which was more marked when the peptide was infused at
1000 ng/kg/min (Supplementary Table S2). However, none of
the treatments applied affected the increase in blood pressure
induced by Ang-II (Supplementary Table S2).
In an additional group of experiments using murine aortic
endothelial cells, increased Nox2 and Nox4, but not dual
oxidase 1 and 2 (Duox1 and Duox2), mRNA expression was
detected in Ang-II-stimulated cells (Supplementary Fig. S7).
Interestingly, whereas Nox2 expression was impaired by cell
pretreatment with Rosu + Bex, Nox4 expression was unaf-
fected by the combination treatment (Supplementary Fig.
S7). In accordance with the results from human cells, neither
drug affected Ang-II-induced Nox2 or Nox4 expression when
evaluated separately (Supplementary Fig. S7).
Suboptimal doses of Rosu + Bex reduce
atherosclerosis development and cell composition
in apoE - / - mice on atherogenic diet
To explore the potential relevance of these findings for
atherosclerosis, 8-week-old apoE- / - mice were fed a high-fat
atherogenic diet for 8 weeks. As expected, animals subjected
to an atherogenic diet presented increased lesion formation and
infiltration of macrophages and T cells within the lesion (Fig.
10). Co-infusion of Rosu at 1.25 mg/kg/day, or oral adminis-
tration of Bex at 10 mg/kg/day, had no effect on these pa-
rameters (Fig. 10). Notably, chronic treatment with the statin
plus Bex substantially decreased lesion formation and the as-
sociated MC infiltration (Fig. 10). Neither glucose level nor the
lipid profile in atherogenic animals was significantly affected
by the different treatments applied (Supplementary Table S3).
Discussion
Combination therapy that simultaneously addresses mul-
tiple mechanisms involved in the pathogenesis of athero-
sclerosis is an attractive emerging concept for preventing
and/or slowing the progression of this disease. Using both
in vitro and in vivo approaches, we provide the first demon-
stration of an anti-inflammatory effect of suboptimal con-
centrations/doses of two commercially available drugs, Rosu
and Bex, in combination.
Mononuclear leukocyte infiltration into the subendothelial
space is a key event in the atherogenic process (31) and
treatment with Rosu or Bex has been shown to limit MC
numbers in atherosclerotic plaques, or their interaction with
the arterial endothelium (27, 55). In this study, stimulation of
arterial endothelial cells with Ang-II, mimicking a dysfunc-
tional endothelium, promoted the adhesion of mononuclear
leukocytes, and this event was clearly reduced by different
combined treatments of Rosu and Bex. Remarkably, this
reduction was achieved with a suboptimal combination of
Rosu (10 nM) and Bex (0.3 lM) since at these concentra-
tions, neither the statin nor the RXR ligand displayed any
FIG. 7. Silencing of endothelial RXRa, PPARa, or PPARc blunted the inhibition of Ang-II-induced HUAEC RhoA
activation and Nox5 expression by the combination of Rosu + Bex at suboptimal concentrations. Cells were transfected
with control siRNA (A), RXRa-specific siRNA (B), PPARa-specific siRNA (C), or PPARc-specific siRNA (D) and
stimulated with Ang-II (1 lM; 1 h) at 47 h post-transfection. In some experiments, cells were pretreated with Rosu (10 nM)
plus Bex (0.3 lM) 20 h before Ang-II challenge. Quantification of RhoA-GTP activity was determined using a colorimetric
G-Lisa RhoA activation assay. Results are the mean – SEM of n = 5–7 independent experiments and presented as percentage
of control siRNA-transfected cells; **p < 0.01 relative to the respective vehicle group, + p < 0.05 relative to the respective
Ang-II stimulated cells. Following a similar protocol but after stimulation with 1 lM Ang-II for 24 h at 24 h post-
transfection, Nox5 expression (E–H) was determined by immunoblotting. Results (mean – SEM of five to six independent
experiments) are expressed as fold increase of Nox5:b-actin of control siRNA-transfected cells. Representative blots are
shown; **p < 0.01 relative to the respective vehicle group, + p < 0.05 relative to the respective Ang-II-stimulated cells.
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significant efficacy when assessed individually. To further
confirm this striking observation in vivo, daily Rosu admin-
istration at a dose four-fold-lower than that required to reduce
atherosclerotic lesion formation (27), or Bex at a dose that
was previously not found to inhibit acute TNFa-induced ar-
teriolar leukocyte adhesion (55), was tested individually or in
combination in mice subjected to chronic Ang-II infusion
(56). In this model of systemic inflammation, arteriolar leu-
kocyte adhesion remained unaltered in Rosu or Bex-treated
animals, whereas combined administration of both drugs
provoked a synergistic inhibitory effect. Furthermore, ath-
eroma formation and MC infiltration in apoE - / - mice sub-
jected to a high-fat diet was clearly diminished in animals
treated with the drug combination, thus validating our in vitro
observations in a relevant in vivo model.
Leukocyte/arterial interactions require both the expression
of several types of CAMs in the endothelium and leukocytes
as well as the presence of counter receptor molecules in the
leukocyte/endothelial cell (14, 31). In addition to adhesion
molecules, chemokines also have the potential to recruit
specific cell types and are involved in the regulation of leu-
kocyte trafficking (14). The ability of Ang-II to increase the
endothelial expression of E-selectin, ICAM-1, and VCAM-1
and also the production of a wide array of leukocyte-
recruiting chemokines is well known (2, 36, 42, 46, 54, 60).
Statins are reported to reduce both the inflammation-induced
expression of these endothelial CAMs and the synthesis of
numerous chemokines (24, 38). More recently, we have
demonstrated decreased expression of E-selectin, ICAM-1,
and VCAM-1 and a decrease in the synthesis of CXCL1 or
CCL2 by the endothelium with RXR agonists in an inflam-
matory environment (55). Therefore, it was perhaps not
surprising that pretreatment of HUAECs with an Rosu + Bex
combination reduced both the expression of CAMs and the
synthesis of different chemokines involved in the MC arrest
evoked by Ang-II. Furthermore, in the in vivo setting, the
combined administration of suboptimal doses of Rosu + Bex,
in addition to attenuating the increased expression of arteri-
olar E-selectin, ICAM-1, VCAM-1, and fractalkine, and the
elevated circulating levels of CXCL1, CCL2, and CCL5 in-
duced by chronic Ang-II exposure also decreased Ang-II-
induced CD11b upregulation on circulating monocytes but
not on neutrophils. This exciting observation may also sug-
gest that this treatment may result in improved vascular
function without compromising other neutrophilic responses
required in host defense.
Having established the action of Rosu + Bex on the
aforementioned components of the canonical leukocyte
recruitment cascade, we sought to determine their effect on
some intracellular signaling cascades triggered by activation
FIG. 8. Combination of Rosu1Bex at suboptimal concentrations reversed the inhibition in nitric oxide (NO)
bioavailability induced by Ang-II in HUAECs. Endothelial cells were incubated with Rosu (10 nM), Bex (0.3 lM), or a
combination of Rosu (10 nM) plus Bex (0.3 lM) for 20 h and then stimulated with Ang-II (1 lM, 4 h), and intracellular NO
was monitored with (DAF-2-FM diacetate) (A). Results (mean – SEM of at least five independent experiments performed in
triplicate); **p < 0.01 relative to the vehicle group, + + p < 0.01 relative to the Ang-II treated group. In additional experi-
ments, endothelial cells were pretreated with the antioxidant apocynin (30 lM for 1 h) or with an RhoA inhibitor (C3
transferase, 2 lg/ml for 4 h) before Ang-II stimulation (1 lM, 1 h). Intracellular NO was monitored with (DAF-2-FM
diacetate) (B). Results (mean – SEM of at least five independent experiments performed in triplicate); **p < 0.01 relative to
the vehicle group, + + p < 0.01 relative to the Ang-II-treated group. Control or siRNA Nox5-transfected HUAEC were
stimulated with Ang-II (1 lM for 4 h), and quantification of intracellular NO content was determined as earlier (C). Results
are the mean – SEM of n = 5 independent experiments performed in triplicate, *p < 0.05 or **p < 0.01 relative to the
respective vehicle group, + + p < 0.01 relative to the respective Ang-II-stimulated cells. In other experiments, cells were
transfected with control siRNA (D), RXRa-specific siRNA (E), PPARa-specific siRNA (F), or PPARc-specific siRNA (G)
and stimulated with Ang-II (1 lM; 4 h) at 44 h post-transfection. In some experiments, cells were pretreated with Rosu
(10 nM) plus Bex (0.3 lM) 20 h before Ang-II challenge and quantification of NO bioavailability was determined. Results
are the mean – SEM of n = 5 independent experiments performed in triplicate, **p < 0.01 relative to the respective vehicle
group, + + p < 0.01 relative to the respective Ang-II-stimulated cells.
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of the AT1 Ang-II receptor. The RhoA-Rho kinase pathway
has been implicated in leukocyte recruitment (4) and RhoA
can be activated by Ang-II, as shown here and in a previous
report (22). We show that targeted knockdown of RhoA in
HUAECs diminished the adhesion of MCs triggered by
Ang-II. Notably, Rosu + Bex abolished Ang-II-induced
RhoA activation. Although blockade of the mevalonate
pathway by statins can prevent the synthesis of isoprenoid
intermediates, such as farnesyl pyrophosphate or ger-
anylgeranyl pyrophosphate that are involved in the post-
translational modification of numerous proteins including
the c subunit of heterotrimeric G proteins such as Rho (5,
19), the concentrations of statins required to inhibit Rho-
kinase are much greater than those applied here (lM range
vs. nM) (38, 51). Furthermore, to the best of our knowledge,
the effect of Bex on RhoA activation has never been
FIG. 9. In vivo effects of suboptimal doses of Rosu1Bex. Ang-II (500 ng/kg/min) or saline was delivered to mice using
osmotic minipumps for 14 days. A group of Ang-II-infused mice was administered with Bex at 10 mg/kg/day by gavage or
with Rosu at 1.25 mg/kg/day delivered through the osmotic minipump. An additional group of Ang-II chronically stimulated
animals was treated with a combination of both compounds. Leukocyte adhesion to arterial endothelium was evaluated in
the cremasteric microcirculation (A). CD11b expression in heparinized whole blood was determined by flow cytometry on
circulating monocytes and neutrophils (B–C). ICAM-1, VCAM-1, E-selectin, and CX3CL1 expression was determined by
immunohistochemistry in the cremasteric arterioles. CD31 staining was used to distinguish vessels (D). Circulating levels of
CINC/KC (E), MCP-1(F), and RANTES (G) were measured by ELISA in plasma samples. Results are the mean – SEM of
n = 5–6 independent experiments. *p < 0.05 or **p < 0.01 relative to vehicle-infused mice; + p < 0.05 or + + p < 0.05 relative
to the Ang-II-infused animals.
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addressed. Therefore, additional studies were undertaken to
address the inhibitory effect of Rosu + Bex on RhoA acti-
vation by Ang-II.
Guided by our initial observations, and given that RhoA is
acknowledged as a primary target of oxidative stress on Ang-
II endothelial stimulation (43), we explored the effect of the
RXR agonist and statin combination on NADPH-oxidase-
derived ROS production. Although Nox2, Nox4, and Nox5
are the most abundant NADPH oxidase isoforms in endo-
thelial cells (29) and are induced by Ang-II (54), only Nox5
appears to play a major role in Ang-II-induced endothelial
adhesiveness since both VCAM-1 and fractalkine upregula-
tion and the subsequent MC arrest were found to be Nox5
mediated (39, 54). We found that Ang-II-induced production
of ROS was attenuated by preincubation of HUAECs with
Rosu + Bex. Moreover, Ang-II-dependent Nox2 and Nox5
expression was significantly reduced by the combined treat-
ment and the former in murine aortic endothelial cells, which
may account for the reduced arteriolar leukocyte adhesion
encountered in animals subjected to chronic Ang-II infusion,
as found in other animal models (11, 41). Furthermore, since
mechanisms through which Ang-II-induced ROS production
activate downstream signaling are elusive, we show here that
RhoA activation is dependent on Nox5/NADPH oxidase
activity. Conversely, knockdown of RhoA in HUAEC or its
pharmacological inhibition affected neither Ang-II-induced
ROS production nor the increase in Nox5 expression, indi-
cating that ROS generation by Nox5 is an upstream regulator
of RhoA activation in this experimental setting.
PPARs are ligand-activated nuclear hormone receptors
that function as transcription factors. The three isoforms of
PPAR (PPARa, PPARc, and PPARb/d) are expressed in the
endothelium and have been described to curb inflammation
in atherosclerosis (3, 40). Ligand binding of PPAR pro-
motes heterodimerization with the RXR receptor, inducing
PPAR transactivation of target genes (40, 55). In this study,
Rosu + Bex were found to enhance RXR, PPARa, and
PPARc protein expression in Ang-II-stimulated HUAECs.
FIG. 10. Suboptimal doses of Rosu1Bex reduced atherosclerosis development and cell composition in apoE - / -
mice on atherogenic diet. Mice were sacrificed at 16 weeks of age after 8 weeks on a low-fat standard diet (control diet),
high-fat atherogenic diet (atherogenic diet), or high-fat atherogenic diet treated with Rosu (1.25 mg/kg/day delivered by
osmotic minipumps), Bex (10 mg/kg/day) by gavage, or with a combination of both drugs. Atheroma lesion was determined
in three to five histological sections per mice (A). The discontinuous lines delineate the limits of the media. Macrophage
(Mac-3 + , B) and T-cell (CD3 + , C) infiltration were also evaluated. Representative images of aortic root cross-sections,
Mac-3 + stained area (brown staining), and CD3 + cells (white arrowheads) for the control or atherogenic diet-fed mice
treated or not with the drugs are shown. Black arrows point to Mac-3 + areas within the lesion. Results are the mean – SEM
of n = 5–7 animals per group. *p < 0.05 or **p < 0.01 relative to values animals subjected to a control diet; + p < 0.05 or
++ p < 0.01 relative to values in untreated animals subjected to an atherogenic diet.
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Importantly, specific knockdown of endothelial RXR,
PPARa, or PPARc reversed the inhibitory effects exerted by
Rosu + Bex on Ang-II-induced mononuclear leukocyte ad-
hesion. Finally, a clear interaction between RXR/PPARa and
RXR/PPARc was revealed on co-incubation with Rosu and
Bex at suboptimal concentrations. Considering that PPARa
or PPARc agonists can inhibit RhoA activation (45, 50) and
exert antioxidant properties (40), it seems likely that inhibi-
tion of Nox5 expression and prevention of ROS generation
inhibit RhoA activation via RXR/PPARa and RXR/PPARc.
Indeed, knockdown of RXRa, PPARa, or PPARc abolished
the inhibitory action of the drug combination on Ang-II-
induced RhoA activation and Nox5 expression. In addition,
RhoA has also been reported to be an upstream regulator of
mitogen-activated protein kinase (MAPK) family members,
such as p38 MAPK (33), and the latter can regulate the
transcription of many genes through its action on downstream
targets such as NF-jB (20, 53); both are involved in in-
flammatory responses such as the MC recruitment induced by
Ang-II (54). Therefore, the inhibition of Ang-II-induced
Nox5 activation and expression by Rosu + Bex combination
may inhibit the activation of RhoA and different MAPKs that
lead to activation of several transcription factors, including
NFjB, and the further regulation of genes encoding different
CAMs and chemokines, which actively participate in the
mononuclear leukocyte recruitment induced by Ang-II
(Supplementary Fig. S8).
Finally, Ang-II impairs endothelial function through super-
oxide anion generation and peroxynitrite formation, and eNOS
inhibition and uncoupling, reducing NO bioavailability (32,
43), and the anti-adhesive properties of NO are widely recog-
nized (17, 21). Here, we report that Ang-II stimulation reduced
NO availability in HUAEC and this reduction was reversed by
pretreatment with Rosu + Bex. In addition, silencing of Nox5
prevented the effects caused by Ang-II and, in the absence of
RXRa, PPARa, or PPARc, the combination of Rosu + Bex was
unable to fully restore endothelial NO bioavailability. These
results suggest that the effects achieved by the drug combina-
tion are mainly due to their antioxidant properties.
In conclusion, this study provides the first evidence
that combined therapy with Rosu and Bex at subopti-
mal concentrations/doses exerts synergistic beneficial
effects on endothelial dysfunction produced by Ang-II.
This anti-inflammatory activity was found to be me-
diated through an Nox5-RhoA-RXR/PPAR-associated
mechanism, linking redox-signaling pathways to MC
recruitment.
Materials and Methods
Human in vitro studies
All investigation with human samples carried out in this
study conforms to the principles outlined in the Declara-
tion of Helsinki and was approved by the institutional
ethics committee at the University Clinic Hospital of Va-
lencia, Spain. Written informed consent was obtained from
all volunteers.
Cell culture
HUAECs were isolated by collagenase treatment (26)
and maintained in human endothelial cell basal medium-2
(EBM-2) supplemented with endothelial growth medium-
2 (EGM-2) and 10% FCS. Cells at passage 1 were grown
to confluence on 24-well culture plates. Before every
experiment, cells were incubated for 16 h in medium
containing 1% FCS and then returned to 10% FCS-
supplemented medium at the commencement of all ex-
perimental protocols.
Leukocyte-HUAEC interactions under flow conditions
HUAECs at passage 1 were grown to confluence and
stimulated with Ang-II (1 lM) for 4 h. Rosu (10–30 nM), Bex
(0.3–1 lM), or combinations of both were added to plates
20 h before Ang-II stimulation. In another set of experiments,
cells were incubated with the ROCK inhibitor Y27632
(10 lM) 1 h before Ang-II stimulation (1 lM, 4 h). Human
MCs were obtained from buffy coats of healthy donors by
Ficoll–Hypaque density gradient centrifugation (37). The
Glycotech flow chamber was assembled and placed onto an
inverted microscope stage, and freshly isolated human MCs
(1 · 106/mL) were then perfused across the endothelial
monolayers (HUAECs or transfected HUAECs). In all ex-
periments, leukocyte interactions were determined after
5 min at 0.5 dyn/cm2. Cells interacting on the surface of the
endothelium were visualized and recorded ( · 20 objective,
· 10 eyepiece) using phase-contrast microscopy (Axio Ob-
server A1; Carl Zeiss microscope).
Flow cytometry
Confluent endothelial cells were stimulated with Ang-II
(1 lM) for 4 h (ICAM-1 and VCAM-1 expression) or 24 h
(CX3CL1 expression). In some experiments, cells were pre-
treated with Rosu (10 nM), Bex (0.3 lM), or a combination of
Rosu (10 nM) plus Bex (0.3 lM) 20 h before Ang-II stimu-
lation. Cells were detached, washed, and incubated at 2 · 106
cells/ml with a 1/100 dilution of primary antibodies against
human VCAM-1 or ICAM-1 in PBS with 0.2% BSA and
0.05% NaN3 for 1 h on ice. Detection of primary antibodies
was performed using the appropriate Alexa Fluor 488-
secondary antibody (dilution 1/250). For fractalkine expres-
sion, cells were incubated with a PE-conjugated mAb against
human CX3CL1 (1/25 dilution) for 1 h on ice in the same
buffer. After two washes, cells were suspended in PBS con-
taining 2% paraformaldehyde. The fluorescence signal of the
labeled cells was then analyzed by flow cytometry (FACS-
Verse Flow Cytometer; BD Biosciences). The expression of
ICAM-1, VCAM-1, and CX3CL1 was expressed as the mean
of fluorescence intensity (MFI).
Real time-polymerase chain reaction
Confluent HUAEC or murine endothelial cells were stim-
ulated with Ang-II (1 lM) for 4 h. In some experiments, cells
were pretreated with Rosu (10 nM), Bex (0.3 lM), or a com-
bination of Rosu (10 nM) plus Bex (0.3 lM) 20 h before Ang-II
stimulation. RNA from endothelial cells was obtained using
Trizol Reagent, and purity and concentration was determined
by the A260/280 ratio. RNA (500 ng) was reverse transcribed
with the Maxima First-Strand cDNA Synthesis kit and am-
plified with Luminar Color HiGreen HigBox qPCR Master
Mix. Reactions were run on a 7900 Fast Real-Time PCR
System, and results were analyzed with the software provided
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by the manufacturer (Applied Biosystems, Life Technologies).
mRNA levels were determined following the 2 -DDCt method
using mouse cyclophilin or human GAPDH as an endogenous
control and normalizing with regard to the control group. The
following primers were designed with Primer Express soft-
ware (Forward: Fw; Reverse: Rv): Human AT1: Fw 5¢ - ACGT
GTCTCAGCATTGATCGAT-3¢ and Rv 5¢-TCGAAGGCGG
GACTTCATT-3¢ and human GAPDH: Fw 5¢- ACCACAG
TCCATGCCATCAC-3¢ and Rv 5¢-TCCACCACCCTGTTG
CTGTA-3¢. Mouse Cyclophilin Fw: 5¢ TGGAGAGCACCAA
GACAGACA-3¢ and Rv 5¢-TGCCGGAGTCGACAATGAT-
3¢; Mouse Nox 2: Fw 5¢TCAAGACCATTGCAAGTGAAC
AC-3¢ and Rv 5¢-TCAGGGCCACACAGGAAAA-3¢: Mouse
Nox 4: Fw5¢- AGCATCTGCATCTGTCCTGAAC-3¢ and .Rv
5¢-ACTGTCCGGCACATAGGTAAAAG-3¢: Mouse Duox 1:
Fw 5¢-AGCTCTCCGGGTCTGCAA-3¢ and Rv 5¢-CACATC
TTCAGCCCTTTGTAGCTT-3¢; Mouse Duox 2: Fw 5¢-GAT
CAGCATCAGACAGGGTTAGG-3¢ and Rv 5¢-TCTTCACG
ACGCGCTTTCT-3¢.
Immunofluorescence
Confluent endothelial cells were grown on glass coverslips
and stimulated with Ang-II (1 lM) for 4 h (ICAM-1 and
VCAM-1 expression) or 24 h (CX3CL1 expression). In some
experiments, cells were pretreated with Rosu (10 nM), Bex
(0.3 lM), or a combination of Rosu (10 nM) plus Bex
(0.3 lM) 20 h before Ang-II stimulation. The cells were fixed
with 4% paraformaldehyde and blocked in a PBS solution
containing 1% BSA. Next, they were incubated for 2 h with
primary mouse antibodies against VCAM-1 or ICAM-1 (1/
100 dilution), followed by a 45 min incubation at room
temperature with an Alexa Fluor 488-conjugated goat anti-
mouse secondary mAb (1/1000 dilution). For fractalkine
detection, samples were incubated overnight with a primary
mouse mAb against human CX3CL1 (1:200 dilution) in a
0.1% BSA/PBS solution at 4C. Cell nuclei were stained with
4¢-6-diamidino-2-phenylindole (DAPI). Images were cap-
tured with an immunofluorescence microscope (Axio Ob-
server A1; Carl Zeiss microscope).
Chemokine detection
Confluent endothelial cells were stimulated with Ang-II
(1 lM) for 4 h. In some experiments, cells were pretreated
with Rosu (10 nM), Bex (0.3 lM), or a combination of
Rosu (10 nM) plus Bex (0.3 lM) 20 h before Ang-II stim-
ulation. Human chemokines GROa (CXCL1), IL-8
(CXCL8), MCP-1 (CCL2), and RANTES (CCL5) were
measured in HUAEC culture supernatants by ELISA. After
coating the plates overnight with the primary antibody,
nonspecific binding sites were blocked with 3% BSA for 1 h.
Supernatants and standards were added to PBS/0.5% BSA/
0.05% NaN3 for 2 h. Biotinylated detector antibodies were
added for 2 h, followed by neutravidin horseradish peroxi-
dase for 1 h. All plate washes were carried out in four cycles
in freshly prepared PBS/0.2% Tween 20. Enhanced K-Blue
TMB substrate was added for 30 min, and the enzyme re-
action was stopped by the addition of 0.19 M sulfuric acid.
Absorbance was read at 450 nm, and the data were processed
by GraphPad Prism software. Results are expressed as pM
chemokine in the supernatant.
Gene knockdown by siRNA
Confluent HUAEC cultures were transfected with either
control or Rho A, Nox 5, RXRa, PPARa, PPARb, and
PPARc-specific siRNA using Lipofectamine RNAiMAX
reagent. Protein expression was determined by immunoblot
of cell lysates after 48 h and compared with the control siR-
NA to determine silencing efficiency.
Western blot and immunoprecipitation
After treatments, cells were washed, detached, collected,
and centrifuged at 15,000 g at 4C for 30 min. Protein content
was determined according to Bradford’s method. Samples
were denatured, subjected to SDS-PAGE using a 10% running
gel, and transferred to nitrocellulose membrane. Nonspecific
binding sites were blocked with 3% BSA in TBS solution, and
blots were incubated overnight with a mouse polyclonal an-
tibody against human RhoA (dilution 1/250), a mouse poly-
clonal antibody against human Nox2 (0.2 lg/mL), a rabbit
polyclonal antibody against human Nox4 (2 lg/ml), a rabbit
polyclonal antibody against human Nox5 (dilution 1/500), a
rabbit polyclonal antibody against human RXRa (dilution 1/
500), a mouse polyclonal antibody against human PPARa
(dilution 1/500), a rabbit polyclonal antibody against human
PPARb/d (dilution 1/500), or a rabbit polyclonal antibody
against human PPARc (dilution 1/500). Subsequently, mem-
branes were washed and incubated for 1 h with the corre-
sponding secondary HRP-linked antibody and developed
using the ECL procedure. Signals were detected using a lu-
minescent reader (FujiFilm image Reader LAS1000; Fuji) and
analyzed with ImageJ software (NIH, Windows free version).
For immunoprecipitation, cell extracts were prepared in
50 mM Tris-HCl (pH 8), 150 mM NaCl, 1% Nonidet P-40,
with protease (1 mM PMSF, 40 lg/ml aprotinin, and 40 lg/ml
leupeptin), and phosphatase (1 mM sodium ortovanadate and
1 mM NaF) inhibitors. Protein (*200 lg) from cell extracts
was incubated with 5 lg of the rabbit polyclonal antibody
against human PPARa or PPARc. Immunocomplexes were
precipitated using anti-rabbit IgG beads following the man-
ufacturer’s instructions and suspended in sample buffer
containing freshly added 50 mM dithiothreitol (DTT). Im-
munoblotting was performed with an antibody against RXRa.
Membranes were developed using horseradish peroxidase-
conjugated rabbit TrueBlot as secondary antibody. Chemi-
luminescent signals were developed with ECL.
RhoA activation assay
HUAECs were grown to 70% confluence in six-well plates.
Then, cells were left untransfected or transfected with a control
siRNA or specific siRNA against Nox5, RXRa, PPARa, or
PPARc using Lipofectamine RNAiMAX. Twenty-four hours
after transfection, cells were pretreated for 20 h with Rosu
(10 nM), Bex (0.3 lM), or a combination of Rosu (10 nM)
plus Bex (0.3 lM) before Ang-II stimulation (1 lM, 1 h) since
Ang-II-induced RhoA activation peaks within the first
hour of challenge (58). In additional assays, untransfected
HUAECs were pretreated with the antioxidant apocynin
(30 lM, 1 h) and subsequently stimulated with Ang-II (1 lM,
1 h). Then, cells were lysed, protein content was determined,
and the RhoA activity was quantified using a commercial
Rho G-LISAassay kit.
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NADPH oxidase activity assay
The activity of NADPH oxidase was measured in HUAECs
by lucigenin-derived chemiluminiscence. HUAECs were pre-
treated for 20 h with Rosu (10 nM), Bex (0.3lM), or a combi-
nation of Rosu (10 nM) plus Bex (0.3lM) before Ang-II
stimulation (1lM, 1 h) since superoxide release induced by Ang-
II is detected after 1 h challenge (10). In some experiments, cells
were pretreated with the antioxidant apocynin (30lM, 1 h) or
with an RhoA inhibitor (C3 transferase, 2 lg/ml, 4 h) before
Ang-II stimulation (1 lM, 1 h). After treatments, HUAECs were
washed with ice-cold PBS, scraped, and centrifuged at
13,000 rpm for 1 min at 4C. The resulting cell pellet was ho-
mogenized in lysis buffer (pH 7.0) containing 50 mM KH2PO4,
1 mM EGTA, and 150 mM sucrose at 4C, and protein content
was determined. Cellular extracts were incubated in PBS con-
taining 5 lM lucigenin and 100 lM NADPH. Thereafter, lumi-
niscence was measured every 10 s for 5 min in an Optocomp
luminometer (MGM Instruments). The enzymatic activity was
expressed as relative light units (RLU)/lg of protein/min.
Measurement of NO production in HUAEC
Intracellular NO was monitored with 4-amino-5-
methylamino-2¢,7¢-difluorofluorescein diacetate (DAF-2-FM
diacetate), a fluorescence indicator of NO that emits fluo-
rescence in response to a reaction with NO, as previously
described (47). To measure intracellular NO, HUAECs were
seeded on 24-well plates. At 80% confluence, HUAECs were
pretreated for 20 h with Rosu (10 nM), Bex (0.3 lM), or a
combination of Rosu (10 nM) plus Bex (0.3 lM) and then
stimulated with Ang-II (1 lM, 4 h). In another set of experi-
ments, cells were pretreated with the antioxidant apocynin
(30 lM, 1 h) or with an RhoA inhibitor (C3 transferase, 2 lg/
ml, 4 h) before Ang-II stimulation (1 lM, 4 h). Finally, cells
were transfected with a control siRNA or specific siRNAs
against Nox5, RXRa, PPARa, or PPARc. Twenty-four hours
after transfection, HUAEC were pretreated for 20 h with or
without Rosu (10 nM) plus Bex (0.3 lM) and then stimulated
with Ang-II (1 lM, 4 h). After completion of the treatments,
cells were loaded with 2.5 lM (DAF-2-FM diacetate) in
EBM-2 supplemented with EGM-2 and 10% FCS for 30 min.
After loading, cells were rinsed with PBS. To quantify the
DAF-related fluorescence, cells were observed under an in-
verted fluorescence Nikon Eclipse Ti-S microscope. Fluor-
escence from five different fields per well was measured
(excitation wavelength: 488 nm; emission wavelength:
515 nm). Fluorescence signals were quantified using NIS-
Elements 3.2 software (Nikon Izasa S.A).
Animal studies
The animal protocol conforms to the Guide for the Care
and Use of Laboratory Animals published by the US National
Institutes of Health (NIH publication No. 85–23, revised
1996) and was approved by the Ethics Review Board of the
School of Medicine, University of Valencia. Colonies of
C57BL/6 mice (22–30 g, Charles River) were bred and
maintained under specific pathogen-free conditions. For the
entire experimental period, the mice were fed with an auto-
claved balanced diet with free access to water.
Ang-II was administered to randomly selected groups of
mice via subcutaneous osmotic minipumps set to deliver
saline or Ang-II (500 ng/kg/min) for 14 days. This dose was
selected based on its mild effects on blood pressure and clear
leukocyte infiltration as previously described (56). A second
group of mice were infused with Ang-II and administered by
gavage with Bex (10 mg/kg/day); a third group was infused
with Ang-II and Rosu (1.25 mg/kg/day delivered by osmotic
minipumps); and a final Ang-II infused group was treated
with a combination of both drugs.
Intravital microscopy
Mice were anesthetized by i.p. injection with a mixture
of xylazine hydrochloride (10 mg/kg) and ketamine hy-
drochloride (200 mg/kg). The mouse cremasteric prepara-
tion used in this study was similar to that previously
described (48). The cremaster muscle was dissected from
the tissues and exteriorized on an optical clear viewing
pedestal. The muscle was cut longitudinally with a cautery
and held flat against the pedestal by attaching silk sutures
to the corners of the tissue. The muscle was then perfused
continuously with warmed bicarbonate-buffered saline (pH
7.4) at a rate of 1 ml/min. The cremasteric microcirculation
was observed using an intravital microscope (Nikon Op-
tiphot-2, SMZ1; Badhoevedorp) equipped with a 50 ·
objective lens (Nikon SLDW; Badhoevedorp) and a
10 · eyepiece. A video camera (Sony SSC-C350P; Koeln)
mounted on the microscope projected the image onto a color
monitor, and the images were CCD recorded for playback
analysis. Cremasteric arterioles (20–40lm in diameter) were
selected for the study, and the diameter was measured online
using a video caliper (Microcirculation Research Institute,
Texas A&M University, College Station, TX). Centerline
blood cell velocity was also measured online using an op-
tical Doppler velocimeter (Microcirculation Research In-
stitute). Vessel blood flow was calculated from the product
of mean RBC velocity (Vmean = centerline blood cell ve-
locity/1.6) and cross-sectional area, assuming cylindrical
geometry. Wall shear rate (c) was calculated based on the
Newtonian definition: c = 8 x (Vmean/Dv) s - 1, in which Dv is
vessel diameter (25).
The number of adherent leukocytes was determined
offline during playback of videotaped images. A leukocyte
was defined as adherent to arteriolar endothelium when it
was stationary for at least 30 s. Leukocyte adhesion was
expressed as the number per 100 lm length of vessel. In
each animal, leukocyte responses were measured in three
to five randomly selected arterioles. At the end of the
experiments, animals were humanely euthanized by anes-
thetic overdose.
Whole mount immunohistochemistry
Once intravital microscopy determinations were per-
formed, mice were sacrificed and the cremaster muscle was
isolated and fixed in 4% paraformaldehyde for 10 minutes.
The protocol followed was similar to that previously de-
scribed (35); briefly, whole-mounted muscles were incubated
for 2 h in 0.2% Triton X-100, 1% BSA, and 0.5% horse serum
in PBS. They were then incubated overnight at 4C with a
primary antibody rabbit anti-mouse CX3CL1 (1/100 dilution)
or eFluor 450-conjugated anti-mouse CD31 (PECAM-1) (1/
100 dilution). Samples were subsequently washed with PBS
and incubated for 1.5 h at room temperature with Alexa Fluor
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488-conjugated donkey anti-rabbit secondary antibody (1/
500 dilution). All antibodies were diluted in 0.1% PBS/BSA.
The muscles were then mounted with Slowfade Gold Re-
agent. Images were acquired with a fluorescence microscope
(Axio Observer A1) equipped with a 40 · objective lens and
a 10 · eyepiece.
Immunohistochemistry
After completion of the intravital microscopy measure-
ments, the cremaster muscle was isolated and fixed in 4%
paraformaldehyde, dehydrated using a graded acetone series
at 4C, and embedded in paraffin wax for assessment of
ICAM-1, VCAM-1, and E-selectin as previously described
(55). Tissue sections (5 lm) were incubated against mouse
ICAM-1, VCAM-1, and E-selectin (all dilutions 1:50) over-
night at 4C and then for a further 60 min at 37C with a
biotinylated anti-rabbit secondary antibody (1:500 dilution),
streptavidin-HRP, and diaminobenzidine substrate. Slides
were counterstained with hematoxylin. Positive staining was
defined as an arteriole displaying a brown reaction product.
Determination of CD11b integrin expression
by flow cytometry
Heparinized whole blood samples were stained for 30 min
with saturated amounts (1:10 dilution) of PE-conjugated anti-
CD115 antibody, VH-450-conjugated anti-Ly6G antibody,
and APC-conjugated anti-CD11b antibody. Red blood cells
were lysed using a commercial lysing solution, and samples
were run in a flow cytometer (FACSVerse Flow Cytometer;
BD Biosciences). The expression of CD11b (CFS fluores-
cence) in monocytes and neutrophils was measured accord-
ing to the expression of CD115 and Ly6G, respectively, and
expressed as the MFI.
Plasma chemokine detection
KC (CXCL1), MCP-1 (CCL2), and RANTES (CCL5) in
mice plasma samples were measured using commercial
ELISA kits. The OD values were recorded on a microplate
reader at 450 nm. The concentrations of cytokines in samples
were calculated from a standard curve generated using re-
combinant chemokines.
Measurement of glucose and lipid profile
Circulating glucose and lipid levels in plasma of mice fasted
overnight were measured using enzymatic procedures (WAKO)
and the Ascensia Elite glucometer (Bayer HealthCare).
Measurement of blood pressure
Systolic blood pressure was measured in conscious mice
using a noninvasive tail cuff system with a photoelectric
sensor (Niprem 645; Cibertec S.A) using a Niprem 1.8 soft-
ware (Cibertec S.A.). During the procedure, animals were
placed in the restrainer tube of a chamber that was kept at
36C (LE5002 Pressure Meter; PANLAB) as previously
described (62). Mice were acclimated to the instrument for 5
continuous days before baseline measurements and then daily
for the remainder 14 days. Blood pressure measurements
were determined every day. Each data are the average of 10
values recorded for each animal and used for analysis.
In an additional group of experiments, Ang-II 1000 ng/kg/
min was administered via subcutaneous osmotic minipumps
for 14 days. A second group of mice were infused with Ang-II
and administered by gavage with Bex (10 mg/kg/day); a third
group was infused with Ang-II and Rosu (1.25 mg/kg/day
delivered by osmotic minipumps); and a final Ang-II-infused
group was treated with a combination of both drugs.
Evaluation of diet-induced atherosclerosis
ApoE - / - (C57BL/6J) female mice were obtained from
Charles River laboratories and kept on a low-fat standard diet
(2.8% fat). At 8 weeks of age, mice were fed with a high-fat
atherogenic diet (10.8% total fat, 0.75% cholesterol) for 8
weeks alone (atherogenic diet group) or treated with Bex
(10 mg/kg/day) by gavage, Rosu (1.25 mg/kg/day delivered
by osmotic minipumps), or a combination of both drugs. The
control mouse group was maintained on a low-fat standard
diet for 8 weeks. After treatments, hearts containing the aortic
root were removed from mice, washed with PBS, fixed with
4% paraformaldehyde/PBS overnight, and paraffin embed-
ded for sectioning and analysis, as described (54).
Atherosclerosis was evaluated in at least three to five aortic
root cross-sections stained with hematoxylin/eosin (16). Le-
sion size was quantified as the intima-to-media ratio in cross-
sections of paraffin-embedded aortic root. For macrophage
quantification in lesions, a rat anti-Mac-3 monoclonal anti-
body (1/200 dilution) was used. After peroxidase inactivation
(H2O2, 0.3%) and blockade with horse serum, samples were
incubated overnight (4C) with the primary antibody. De-
tection was performed with a biotin-conjugated goat anti-rat
secondary antibody (1/300 dilution) followed by HRP-
streptavidin and DAB substrate incubation. Slides were
counterstained with hematoxylin and mounted with EU-
KITT. For T-cell detection within the lesion, aortic root
cross-sections were blocked as described earlier, incubated
overnight with an anti-CD3 antibody (1/75 dilution) followed
by an incubation for 1 h at room temperature with an Alexa
Fluor 488-conjugated goat anti-rabbit secondary antibody,
and mounted with Slow-Fade Gold antifade reagent. Pre-
parations were analyzed by fluorescent microscopy with an
inverted fluorescent microscope (Axio Observer A1).
Additional materials
Ang-II was purchased from Calbiochem. Bex, and Rosu
were obtained from Axxora (BioVision). Endothelial basal
medium-2 (EMB-2), EGM-2, and FCS were purchased from
Lonza Iberica. Ketamine and xylazine hydrochloride were
supplied by ORION Pharma. Apocynin, mouse anti-human b-
actin mAb (clone AC-15), and anti-Nox5 C-terminal poly-
clonal antibody produced in rabbit that detects the 86 kDa
band, hematoxylin, and Y27632 were purchased from Sigma-
Aldrich. Nevertheless, there are other antibodies in the litera-
ture that can detect a 70 kDa band of Nox5 (39). The rabbit
polyclonal against mouse CX3CL1, the PE-conjugated rat
monoclonal against mouse CD31 (clone 390), and TrueBlot
Anti-Rabbit Ig IP beads were provided by eBioscience. The
PE-conjugated mouse monoclonal against human CX3CL1
(clone 51637), primary mouse monoclonal mAb against hu-
man CX3CL1 (clone 81506), primary chicken mAb against
mouse E-selectin, human GRO-a, IL-8, MCP-1, and RANTES
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antibody pairs were purchased from R&D Systems. The
mouse monoclonal anti-human RhoA Ab, rabbit polyclonal
anti-human Nox4, the rabbit polyclonal anti-human PPARa
Ab, the rabbit polyclonal anti-human PPARb/d Ab, and the
rabbit polyclonal anti-human PPARc Ab were supplied by
Abcam. The primary mouse mAb against human VCAM-1,
the primary mouse mAb against human ICAM-1, the mouse
monoclonal anti-human Nox2 (clone NL7) Ab, and the DAB
substrate was purchased from Serotec. Sodium heparin
(5000 U/ml or 50 mg/ml) was supplied by Pharmaceutical
Laboratories Rovi SA. Ficoll-Paque TM PLUS and ECL
developer were purchased from GE Healthcare. DAPI, DAF-
2-FM diacetate and Alexa Fluor 488-conjugated secondary
antibodies were from Molecular Probes-Invitrogen. The sec-
ondary Abs, HRP-linked anti-goat, HRP-linked anti-rabbit,
HRP-linked anti-mouse, and the anti-mouse CD3 antibody
were purchased from Dako. HRP-Streptavidin was from
LABVISION Corporation. The RhoA-specific siRNA and
Ultra TMB-ELISA were purchased from Thermo Fisher Sci-
entific, Inc. Nox5, RXRa, PPARa, PPARb/d, and PPARc-
specific siRNA were purchased from Dharmacon. The Alzet
2004 osmotic minipumps, C57BL/6 and ApoE- / - mice were
from Charles River. The primary rabbit mAb against mouse
VCAM-1, primary rabbit mAb against mouse ICAM-1, the
PE-conjugated mAb against mouse CD115 (clone AF598), the
VH-450-conjugated mAb against mouse Ly6G (clone 1A8)
and APC-conjugated mAb against mouse CD11b (clone M1/
70), and the lysing solution were from BD Pharmingen. The
biotinylated anti-rabbit secondary Ab, rabbit polyclonal
against PPARc, rabbit polyclonal against RXRa, mouse
monoclonal against PPARa, the anti-Mac-3 mAb (clone M3/
84), and the biotin-conjugated goat anti-rat secondary Ab were
purchased from Santa Cruz Biotechnology. The EUKITT was
provided by Deltalab. The G-LISA RhoA activation assay
Biochem kit and cell-permeable C3 transferase (RhoA inhib-
itor) were from Cytoskeleton, Inc. Slowfade Gold Reagent and
lipofectamine RNAiMAX were from Invitrogen. The mouse
RANTES ELISA kit was for RayBiotech. Recombinant hu-
man GRO-a, IL-8, MCP-1, and RANTES were acquired from
Peprotech. Murine aortic endothelial cells were from Innoprot.
Maxima First-Strand cDNA Synthesis kit and Luminar Color
HiGreen HigBox qPCR Master Mix were from Fermentas,
Thermo Fisher Scientific. The low-fat standard diet was from
Panlab. The high-fat atherogenic diet (10.8% total fat, 0.75%
cholesterol) was acquired from Sniff.
Statistical analysis
Values were expressed as mean – SEM. Differences be-
tween two groups were determined by paired or unpaired
Student’s t test, as appropriate. Data within multiple groups
were compared using an analysis of variance (one-way AN-
OVA), including a Newman–Keuls post hoc test for multiple
comparisons. Data were considered statistically significant
when p < 0.05.
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CAM¼ cell adhesion molecule
DAPI¼ 4¢-6-diamidino-2-phenylindole
EBM-2¼ endothelial cell basal medium-2
EGM-2¼ endothelial growth medium-2
ELISA¼ enzyme-linked immunoassay
eNOS¼ endothelial nitric oxide synthase
GROa¼ growth regulated oncogene-a
HUAEC¼ human umbilical artery endothelial cells






PPAR¼ peroxisome proliferator-activated receptor
RANTES¼ regulated on activation, normal T cell
expressed and secreted
ROCK¼Rho-associated protein kinase
ROS¼ reactive oxygen species
Rosu¼ rosuvastatin
RXR¼ retinoid X receptor
siRNA¼ small interfering RNA
TNFa¼ tumor necrosis factor-a
VCAM-1¼ vascular cell adhesion molecule-
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